Sectors
OKUR
OnKure Therapeutics, Inc.
4.05
11 x 3.64
1 x 4.40
bid
ask
-
0.01
0.32%
09:38 AM
timesize
| Ytd | 39.55% | |
| 1y | 99.36% |
3.98
day range
4.11
1.93
52 week range
5.38
| Open | 4.07 | Prev Close | 4.06 | Low | 3.98 | High | 4.11 | Mkt Cap | 55.34M |
| Vol | 3.23K | Avg Vol | 302.33K | EPS | -3.50 | P/E | -1.16 | Forward P/E | -2.64 |
| Beta | 0.29 | Short Ratio | 19.81 | Inst. Own | 53.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 4.24 | 200-d Avg | 3.60 | 1yr Est | 34.75 |
| Income Statement | |||
| Operating Expenses | 16.90M | ||
| Research and Development Expense | 12.61M | ||
| Selling, General and Administrative Expense | 4.29M | ||
| Operating Income | -16.90M | ||
| Net Income | -15.35M | ||
| Net Income Common Stock | -15.35M | ||
| Net Income Common Stock (USD) | -15.35M | ||
| Consolidated Income | -15.35M | ||
| Earnings per Basic Share | -0.31 | ||
| Earnings per Basic Share (USD) | -0.31 | ||
| Earnings per Diluted Share | -0.31 | ||
| Earning Before Interest & Taxes (EBIT) | -15.35M | ||
| Earning Before Interest & Taxes (USD) | -15.35M | ||
| Weighted Average Shares | 49.87M | ||
| Weighted Average Shares Diluted | 49.87M | ||
| Balance Sheet | |||
| Cash and Equivalents | 166.50M | ||
| Cash and Equivalents (USD) | 166.50M | ||
| Investments | 9.88M | ||
| Investments Current | 9.88M | ||
| Current Assets | 177.68M | ||
| Property, Plant & Equipment Net | 1.27M | ||
| Total Assets | 179.35M | ||
| Debt Current | 336.00K | ||
| Total Debt | 926.00K | ||
| Current Liabilities | 6.64M | ||
| Debt Non-Current | 590.00K | ||
| Total Liabilities | 7.25M | ||
| Accumulated Retained Earnings (Deficit) | -244.74M | ||
| Accumulated Other Comprehensive Income | -13.00K | ||
| Shareholders Equity | 172.11M | ||
| Shareholders Equity (USD) | 172.11M | ||
| Assets Non-Current | 1.68M | ||
| Total Debt (USD) | 926.00K | ||
| Liabilities Non-Current | 602.00K | ||
| Trade and Non-Trade Payables | 2.00M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 188.00K | ||
| Net Cash Flow from Financing | -5.38M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -25.60M | ||
| Capital Expenditure | -3.00K | ||
| Issuance (Purchase) of Equity Shares | -5.38M | ||
| Net Cash Flow from Investing | -9.87M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -9.87M | ||
| Net Cash Flow from Operations | -10.35M | ||
| Share Based Compensation | 3.05M | ||